ストックスクリーナーアプリを入手
0.9448
7.37%
-0.0752
プレマーケット:
.95
0.0052
+0.55%
前日終値:
$1.02
開ける：
$0.9903
24時間の取引高:
181.48K
Relative Volume:
0.45
時価総額：
$8.24M
収益：
$6.74M
当期純損益:
$-14.74M
株価収益率:
-0.4201
EPS:
-2.2491
ネットキャッシュフロー:
$-18.31M
1週間 パフォーマンス:
-14.11%
1か月 パフォーマンス:
-12.52%
6か月 パフォーマンス:
-24.42%
1年 パフォーマンス:
-35.73%
1日の値動き範囲:
$0.91
$1.00
1週間の範囲:
$0.91
$1.19
52週間の値動き範囲:
$0.91
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.9448 | 8.89M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-08 | 開始されました | ROTH Capital | Buy |
| 2021-07-29 | 開始されました | Aegis Capital | Buy |
| 2020-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2013-12-16 | 開始されました | Oppenheimer | Outperform |
Evogene Ltd (EVGN) 最新ニュース
Why did EVGN shares drop more than 14% today? - MSN
Evogene Ltd. Expands Google Cloud Collaboration to Integrate AI Agents into ChemPass AI™ - iGrow News
Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases - Finviz
AI-designed drugs take aim at inflammatory diseases affecting millions - Stock Titan
Evogene expands Google Cloud collaboration to enhance AI platform By Investing.com - Investing.com South Africa
Evogene announces warrant inducement deal for $3.4 million By Investing.com - Investing.com Nigeria
Evogene Enters Warrant Inducement Agreement Amid Stock Decline - Intellectia AI
Why Did EVGN Shares Drop More Than 14% Today? - Asianet Newsable
Evogene announces warrant inducement deal for $3.4 million - Investing.com
Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan
Evogene stock rises as company expands Google Cloud collaboration - Investing.com India
Evogene Ltd. Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI?? - marketscreener.com
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI - Finviz
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™ - PR Newswire
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - Finviz
Evogene appoints two professors to scientific advisory board By Investing.com - Investing.com South Africa
Evogene Ltd. Appoints Prof. John J. Irwin and Prof. Dan T. Major to Its Scientific Advisory Board - marketscreener.com
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board - Finviz
Evogene appoints two professors to scientific advisory board - Investing.com
Evogene, Shanghai Lishan Sign Exclusive Licensing Deal For Global Development of Microbiome Cancer Drug BMC128 - Voice Of HealthCare
Investment Recap: Is Evogene Ltd. in a consolidation phase2025 Price Momentum & High Return Trade Guides - baoquankhu1.vn
Evogene and Lishan Biotech Sign Exclusive Licensing Agreement - Intellectia AI
Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech By Investing.com - Investing.com Nigeria
Evogene (EVGN) Stock: Stabilizes as BMC128 Deal Targets Renal and Lung Cancer Growth - parameter.io
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer - Finviz
Evogene Joins Forces with Unravel Biosciences to Combat Neurological Disorders - StocksToTrade
Evogene Licenses Microbiome-Based Cancer Therapeutic BMC128 To Shanghai Lishan Biopharmaceuticals - Nasdaq
Evogene stock soars after licensing deal for cancer therapeutic By Investing.com - Investing.com India
Evogene stock soars after licensing deal for cancer therapeutic - Investing.com
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Excl - GuruFocus
Evogene’s Biomica Grants Lishan Biotech Global Rights to Microbiome Cancer Drug BMC128 - TipRanks
Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech - Investing.com
Earnings Recap: Is Evogene Ltd impacted by rising ratesMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Evogene (NASDAQ:EVGN) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
Aug Retail: Is Evogene Ltd attractive for institutional investorsJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - baoquankhu1.vn
Jobs Data: How cyclical is SHOTWs revenue stream2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
S P Trends: Is McDonalds Corporation stock technically oversoldIndex Update & Reliable Intraday Trade Alerts - baoquankhu1.vn
MACD Signal: Can Evogene Ltd disrupt its industryPortfolio Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Evogene Announces CFO Resignation and Finance Leadership Transition - TipRanks
Evogene announces CFO resignation and interim appointment By Investing.com - Investing.com Nigeria
Evogene announces CFO resignation and interim appointment - Investing.com
Evogene (NASDAQ: EVGN) plans CFO change as VP Finance steps up to new role - Stock Titan
Evogene Ltd. Announces CFO Changes - marketscreener.com
Breakout Watch: Is Evogene Ltd stock heavily shortedJuly 2025 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
US Market Wrap: How Evogene Ltd stock performs in weak economyNew Guidance & Expert Verified Stock Movement Alerts - Bộ Nội Vụ
Published on: 2026-01-11 04:12:19 - Улправда
Portfolio Shifts: Can Evogene Ltd stock sustain market leadershipDividend Hike & Low Risk Entry Point Guides - moha.gov.vn
HOKA Model Insights: Will Evogene Ltd. stock benefit from upcoming earnings reportsTrail vs Road Selection & updated model highlights and notes - Улправда
Is Evogene Ltd. stock undervalued vs historical averages2025 Buyback Activity & Weekly Watchlist for Hot Stocks - Улправда
Why Evogene Ltd. stock appeals to dividend seekers2025 EndofYear Setup & Real-Time Volume Spike Alerts - Улправда
Evogene Ltd (EVGN) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):